Photodynamic therapy for Barrett's esophagus: Does light still have a role?

Endoscopy

Volumn 40, Issue 12, 2008, Pages 1021-1025

  Wang, Kenneth K ^a,b   Lutzke, L ^a   Borkenhagen, L ^a   Westra, W ^a   Song, M W K ^a   Prasad, G ^a   Buttar, N S ^a  

^a MAYO CLINIC   (United States)

^b Department of Gastroenterology E19B ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID; ANTIHISTAMINIC AGENT; OMEPRAZOLE; PHOTOFRIN;

BARRETT ESOPHAGUS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DYSPLASIA; ESOPHAGOSCOPY; ESOPHAGUS CANCER; ESOPHAGUS MUCOSA; ESOPHAGUS STRICTURE; FOLLOW UP; GENETIC DISORDER; HUMAN; LOW LEVEL LASER THERAPY; MONOTHERAPY; NAUSEA AND VOMITING; NEODYMIUM LASER; OXYGENATION; PHOTODYNAMIC THERAPY; PHOTOSENSITIVITY; PRIORITY JOURNAL; REMISSION; REVIEW; THORAX PAIN;

ADENOCARCINOMA; BARRETT ESOPHAGUS; BIOPSY; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; EQUIPMENT DESIGN; ESOPHAGEAL NEOPLASMS; ESOPHAGOSCOPES; ESOPHAGUS; FOLLOW-UP STUDIES; HEMATOPORPHYRIN PHOTORADIATION; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PHOTOCHEMOTHERAPY; PRECANCEROUS CONDITIONS; SURVIVAL RATE;

EID: 58149096840     PISSN: 0013726X     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0028-1103405     Document Type: Review

References (32)

1. s esophagus: not yet ready for the premier league of endoscopic interventions. Gastrointestinal Endoscopy 2005; 62: 503-507
2. Wilson BC, Patterson MS, Wilson BC, Patterson MS. The physics, biophysics and technology of photodynamic therapy. Phys Med Biol 2008; 53: 61-R109
3. Birkmeyer JD, Stukel TA, Siewers AE et al. Surgeon volume and operative mortality in the United States. N Engl J Med 2003; 349: 2117-2127
4. Lightdale CJ, Heier SK, Marcon NE et al. Photodynamic therapy with porfimer sodium versus thermal ablation therapy with Nd:YAG laser for palliation of esophageal cancer: a multicenter randomized trial. Gastrointest Endosc 1995; 42: 507-512
5. Dougherty T. Photodynamic therapy for early esophageal cancer [abstract]. International Photodynamic Therapy Association Meeting 1990
6. Laukka MA, Wang KK. Initial results using low-dose photodynamic therapy in the treatment of Barrett's esophagus. Gastrointest Endosc 1995; 42: 59-63
7. Overholt BF, Panjehpour M. Barrett's esophagus: photodynamic therapy for ablation of dysplasia, reduction of specialized mucosa, and treatment of superficial esophageal cancer. Gastrointest Endosc 1995; 42: 64-70
8. Overholt BF, Lightdale CJ, Wang KK et al. Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomized phase III trial. [Erratum appears in Gastrointest Endosc 2006; 63:359]. Gastrointest Endosc 2005; 62: 488-498
9. Overholt BF, Wang KK, Burdick JS et al. Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett's high-grade dysplasia. Gastrointest Endosc 2007; 66: 460-468
10. Pech O, Gossner L, May A et al. Long-term results of photodynamic therapy with 5-aminolevulinic acid for superficial Barrett's cancer and high-grade intraepithelial neoplasia. Gastrointest Endosc 2005; 62: 24-30
11. Hage M, Siersema PD, van Dekken H et al. 5-aminolevulinic acid photodynamic therapy versus argon plasma coagulation for ablation of Barrett's oesophagus: a randomised trial. Gut 2004; 53: 785-790
12. Peters F, Kara M, Rosmolen W et al. Poor results of 5-aminolevulinic acid-photodynamic therapy for residual high-grade dysplasia and early cancer in Barrett esophagus after endoscopic resection. Endoscopy 2005; 37: 418-424
13. Mackenzie GD, Jamieson NF, Novelli MR et al. How light dosimetry influences the efficacy of photodynamic therapy with 5-aminolaevulinic acid for ablation of high-grade dysplasia in Barrett's esophagus. Lasers in Med Sci 2008; 23: 203-210
14. Hur C, Nishioka NS, Gazelle GS. Cost-effectiveness of photodynamic therapy for treatment of Barrett's esophagus with high grade dysplasia. Dig Dis Sci 2003; 48: 1273-1283
15. Shaheen NJ, Inadomi JM, Overholt BF, Sharma P. What is the best management strategy for high grade dysplasia in Barrett's oesophagus? A cost effectiveness analysis. Gut 2004; 53: 1736- 744
16. Comay D, Blackhouse G, Goeree R et al. Photodynamic therapy for Barrett's esophagus with high-grade dysplasia: a cost-effectiveness analysis. Can J Gastroenterol 2007; 21: 217-222
17. Comay D, Blackhouse G, Goeree R et al. Photodynamic therapy for Barrett's esophagus with high-grade dysplasia: a cost-effectiveness analysis. Can J Gastroenterol 2007; 21: 217-222
18. Prasad GA, Wang KK, Buttar NS et al. Predictors of stricture formation after photodynamic therapy for high-grade dysplasia in Barrett's esophagus. Gastrointest Endosc 2007; 65: 60-66
19. Prasad GA, Wang KK, Buttar NS et al. Long-term survival following endoscopic and surgical treatment of high-grade dysplasia in Barrett's esophagus. Gastroenterology 2007; 132: 1226-1233
20. Sharma VK, Wang KK, Overholt BF et al. Balloon-based, circumferential, endoscopic radiofrequency ablation of Barrett's esophagus: 1-year follow-up of 100 patients. Gastrointest Endosc 2007; 65: 185-195
21. Mörk H, Barth T, Kreipe HH et al. Reconstitution of squamous epithelium in Barrett's oesophagus with endoscopic argon plasma coagulation: a prospective study. Scand J Gastroenterol 1998; 33: 1130-1134
22. Van Laethem JL, Cremer M, Peny MO et al. Eradication of Barrett's mucosa with argon plasma coagulation and acid suppression: immediate and mid term results. Gut 1998; 43: 747-751
23. Cheung R, Solonenko M, Busch TM et al. Correlation of in vivo photosensitizer fluorescence and photodynamic-therapy-induced depth of necrosis in a murine tumor model. J Biomed Optics 2003: 8: 248-252
24. Solonenko M. In vivo reflectance measurement of optical properties, blood oxygenation and motexafin lutetium uptake in canine large bowels, kidneys and prostates. Phys Med Biol 2002; 47: 857-873
25. Sessler JL, Miller RA. Texaphyrins: new drugs with diverse clinical applications in radiation and photodynamic therapy. Biochem Pharmacol 2000; 59: 733-739
26. Vargas A, Eid M, Fanchaouy M et al. In vivo photodynamic activity of photosensitizer-loaded nanoparticles: formulation properties, administration parameters and biological issues involved in PDT outcome. Eur J Pharm Biopharm 2008; 69: 43-53
27. Saw CL, Heng PW, Oliva M et al. Potentiation of the photodynamic action of hypericin. J Environ Pathol Toxicol Oncol 2008; 27: 23-33
28. Minnes R, Weitman H, You Y et al. Dithiaporphyrin derivatives as photosensitizers in membranes and cells. J Phys Chem B 2008; 112: 3268-3276
29. Cole CD, Liu JK, Sheng X et al. Hypericin-mediated photodynamic therapy of pituitary tumors: preclinical study in a GH4C1 rat tumor model. J Neurooncol 2008; 87: 255-261
30. Trachtenberg J, Bogaards A, Weersink RA et al. Vascular targeted photodynamic therapy with palladium-bacteriopheophorbide photosensitizer for recurrent prostate cancer following definitive radiation therapy: assessment of safety and treatment response. J Urol 2007; 178: 1974-1979: discussion 1979
31. Taquet JP, Frochot C, Manneville V et al. Phthalocyanines covalently bound to biomolecules for a targeted photodynamic therapy. Curr Med Chem 2007; 14: 1673-1687
32. Prasad GA, Wang KK, Halling KC et al. Utility of biomarkers in prediction of response to ablative therapy in Barrett's esophagus. Gastroenterology 2008; 135: 370-379